Get started
Work

Supplementary Figure 1 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Year: 2023
Type: supplementary-materials
Abstract: The toxicity profiles were similar between the treatment arms. (A) There was no difference in the total number of graded adverse events (AE) between arms of the trial. (B) There was no significant difference in the maximum local and systemic toxicity experienced by each patient between arms of the trial.
DOI: 10.1158/1078-0432.22478778
Authors: G. Travis Clifton, Diane Hale, Timothy J. Vreeland, Annelies T. Hickerson, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne V. Philips, Jason J. Lukas, Jarrod P. Holmes, George E. Peoples, Elizabeth A. Mittendorf
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361889493
Cites:
Cited by:
Related to: 10